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A B S T R A C T
Objective: The aim of this study was to evaluate the eﬀects of omega-3 and vitamin E co-supplementation on
parameters of mental health and gene expression related to insulin and inﬂammation in subjects with polycystic
ovary syndrome (PCOS).
Methods: Forty PCOS women were allocated into two groups and treated with 1000 mg omega-3 fatty acids plus
400 IU vitamin E supplements (n = 20) or placebo (n = 20) per day for 12 weeks. Parameters of mental health
were recorded at baseline and after the 12-week intervention. Gene expression related to insulin and in-
ﬂammation were measured in blood samples of PCOS women.
Results: After the 12-week intervention, compared with the placebo, omega-3 and vitamin E co-supplementation
led to signiﬁcant improvements in beck depression inventory total score (− 2.2±2.0 vs. − 0.2±1.3, P =
0.001), general health questionnaire scores (− 5.5±4.6 vs. − 1.0± 2.3, P< 0.001) and depression anxiety
and stress scale scores (− 7.2±5.2 vs. − 1.3± 1.3, P<0.001). Compared with the placebo, omega-3 and
vitamin E co-supplementation could up-regulate peroxisome proliferator-activated receptor gamma (PPAR-γ)
expression (P = 0.04) in peripheral blood mononuclear cells (PBMC) of PCOS women. In addition, compared
with the placebo, omega-3 and vitamin E co-supplementation down-regulated interleukin-8 (IL-8) (P = 0.003)
and tumor necrosis factor alpha (TNF-α) expression (P = 0.001) in PBMC of PCOS women. There were no
signiﬁcant diﬀerence between-group changes in glucose transporter 1 (GLUT-1), IL-6 and transforming growth
factor beta (TGF-β) in PBMC of PCOS women.
Conclusion: Omega-3 and vitamin E co-supplementation was eﬀective in improving parameters of mental health,
and gene expression of PPAR-γ, IL-8 and TNF-α of women with PCOS.
1. Introduction
Previous reports suggest that insulin resistance in women with
polycystic ovary syndrome (PCOS) disrupt reproductive functions
through enhanced thecal androgen production and suppressing ovarian
follicular development (Barber et al., 2016). One hypothesis is that
elevated concentrations of androgens and insulin resistance in PCOS
women increase the risk for depression (Cesta et al., 2016). Earlier,
several studies have demonstrated that subjects with PCOS suﬀer from
impaired emotional well-being, including anxiety and depression (Jedel
et al., 2010), and decreased quality of life (Barnard et al., 2007). Hy-
perinsulinemia in PCOS subjects is also associated with adverse meta-
bolic changes, including dysglycemia and dyslipidemia (Morin-
Papunen et al., 2000). In addition, prior reports had suggested that
PCOS is associated with elevations in various inﬂammatory markers
(Sirmans et al., 2012). Current evidence suggests that inﬂammation is
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an independent risk factor for decreased myocardial contractility, in-
creased hypertrophy, apoptosis, heart rate variability as well as cardi-
ovascular diseases (CVD) (Haensel et al., 2008).
Considering that insulin resistance syndrome and inﬂammation
participate in the development of PCOS, it is perhaps not strange that
lifestyle changes and the use of supplements including omega-3 and/or
vitamin E due to improvement in insulin sensitivity and inﬂammation,
remain the most eﬀective treatment strategy for PCOS subjects
(Rahmani et al., 2017). Previously, the eﬀects of single omega-3 or
vitamin E supplementation on parameters of mental health and gene
expression related to insulin and inﬂammation in animal models and
subjects without PCOS have been evaluated. Some studies have found
that omega-3 fatty acids supplementation, administered either adjunc-
tively or as monotherapy, signiﬁcantly decreased depression symptom
severity in pediatric and adolescent patients (Wozniak et al., 2007;
McNamara et al., 2014). In addition, Gautam et al. (2012) observed that
antioxidant supplementation for 6 weeks to subjects with stress-induced
psychiatric disorders resulted in a signiﬁcant reduction in anxiety and
depression scores. Zaree et al. (2015) shown that treating granulosa
cells with eicosapentaenoic acid (EPA) up-regulated peroxisome pro-
liferator-activated receptor gamma (PPAR-γ) levels. Suppression of
tumor necrosis factor alpha (TNF-α) expression by EPA was also re-
ported in human monocytic THP-1 cells due to its inhibitory eﬀect on
nuclear factor-kappaB (NF-kB) activation (Zhao et al., 2004). Moreover,
vitamin E supplementation in an animal model could up-regulate
mRNA expressions of PPAR-γ (Tang et al., 2014). These documents
might support the importance of omega-3 and vitamin E co-supple-
mentation in subjects with PCOS.
Previously, omega-3 and vitamin E co-supplementation have been
used by other researchers. Vitamin E intake can decrease the oxidative
stress induced by omega-3 fatty acids. Therefore, their co-supple-
mentations work better than single supplementation (Alves Luzia et al.,
2015). In addition, few studies have showed that omega-3 and vitamin
E co-supplementation might have a strong synergistic eﬀect on meta-
bolic proﬁles. For instance, Ramezani et al. (2015) observed no sig-
niﬁcant eﬀects of omega-3 supplementation on serum adiponectin le-
vels, however when the combination of omega-3 and vitamin E was
administered, an increased adiponectin concentrations were found.
According to our knowledge, data on the eﬀects of omega-3 and vi-
tamin E co-supplementation on parameters of mental health and gene
expression levels involved in insulin and inﬂammation signaling
pathway in subjects with PCOS are scarce. We investigated this aim by
conducting the eﬀects of omega-3 and vitamin E co-supplementation on
parameters of mental health and gene expression levels related to in-
sulin and inﬂammation in PCOS subjects.
2. Materials and methods
2.1. Trial design and subjects
This randomized double-blind placebo-controlled clinical trial, re-
gistered in the Iranian registry of clinical trials (http://www.irct.ir:
IRCT201605215623N79), was performed at the Kosar clinic aﬃliated
to Arak University of Medical Sciences (AUMS), Arak, Iran between
March 2016 and June 2016. Inclusion criteria were subjects with PCOS
according to the Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus
Workshop Group (2004) and age range of 18–40 years. The research
was approved by the research ethics committee of AUMS (ethical ap-
proval number: IR.ARAKMU.REC.1394.335). Smoking, intake of
omega-3 fatty acids and/or vitamin E supplements within the last 3
months, intake of anti-inﬂammatory or antidiabetic drugs, pregnancy,
other causes of hyperandrogenism and/or anovulation, including
Cushing's syndrome, androgen-secreting tumors, hyperprolactinemia
and thyroid dysfunction, and females not living in Arak area were the
exclusion criteria of the study.
2.2. Study design
At ﬁrst, forty PCOS women were matched according to BMI (< 25
and≥ 25 kg/m2) and age (< 30 and≥ 30 y). Then, PCOS women were
randomized into two groups to receive either 1000 mg omega-3 fatty
acids plus 400 IU vitamin E supplements (n = 20) or placebo (paraﬃn)
(n = 20) per day for 12 weeks. Shape and size of supplements and
placebos capsules were similar and manufactured by Barij Essence
(Kashan, Iran). All participants were advised to maintain their routine
dietary habits without any changes in their other lifestyle factors such
as physical activity during the study. All women completed 3-day food
records and three physical activity records as metabolic equivalents
(METs) at weeks 0, 3, 6, 9 and 12 of the treatment.
2.3. Treatment adherence
To evaluate the compliance, subjects were asked to bring the
medication container. To ensure adherence, participants received a
short message on their cell phones to take the supplements daily.
2.4. Assessment of anthropometric measures
At baseline and end-of-trial, all subjects underwent standard an-
thropometric measurements: height and weight (Seca, Hamburg,
Germany). BMI was calculated as weight in kg divided by height in
meters squared. Waist circumference (WC) was evaluated at the
minimum circumference between the iliac crest and the last rib. Hip
circumference (HC) was quantiﬁed at the maximum protuberance of
the buttocks.
2.5. Clinical assessments
Clinical assessments included determinations of hirsutism using a
modiﬁed Ferriman Gallwey (mFG) scoring system (Hatch et al., 1981).
2.6. Assessment of outcomes
Parameters of mental health were considered as the primary out-
come and PPAR-γ, glucose transporter 1 (GLUT-1) expression, inter-
leukin-1 (IL-1), interleukin-8 (IL-8), TNF-α and transforming growth
factor beta (TGF-β) expression were considered as the secondary out-
comes.
2.7. Assessment of mental health
Mental health was judged with beck depression inventory (BDI),
general health questionnaire-28 (GHQ-28) and depression anxiety and
stress scale (DASS) at baseline and the end of treatment. BDI is a self-
compiled questionnaire of 21 items in multiple choice format (Beck
et al., 1961). The GHQ-28 comprises 28-item consisting of 4 subscales:
somatic symptoms, anxiety and insomnia, social dysfunction and severe
depression (Goldberg and Hillier, 1979). DASS questionnaire consists of
three 14-item self-report scales that measure depression, anxiety and
stress (Crawford and Henry, 2004).
2.8. Isolation of lymphocyte cells
At baseline and endpoint of the intervention, 10 mL samples of
fasting blood were taken at Arak reference laboratory. Then, lympho-
cyte cells were extracted from blood samples of subjects with PCOS by
the use of a 50% percoll (Sigma-Aldrich, Dorset, UK). Samples were
taken for cell count and viability testing by trypan blue, RNA and DNA
extraction (Dunkley et al., 2008).
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2.9. RNA extraction and real-time PCR
To RNA extraction, we used the RNX-plus kit (Cinnacolon, Tehran,
Iran). Following extraction of the total RNAs from each sample, RNA
quantiﬁcation were performed by UV spectrophotometer. Each samples
OD 260/280 ratio between 1.7 and 2.1 was intended showing no con-
tamination with both protein and DNA (Dunkley et al., 2008). The
isolated RNA was reverse transcribed to cDNA library using moloney
murine leukemia virus reverse transcriptase. Gene expression of PPAR-
γ, GLUT-1, IL-1, IL-8, TNF-α and TGF-β were evaluated by quantitative
RT-PCR, using the LightCycler technology (Roche Diagnostics, Rotk-
reuz, Switzerland) with SYBR green detection and Amplicon Kit
(Table 1). Glyceraldehyde-3-phosphate dehydrogenase primers were
used as housekeeping gene. To design primers, Primer Express Software
(Applied Biosystems, Foster City) and Beacon designer software (Ta-
kaposizt, Tehran, Iran) were used. Relative transcription levels were
calculated by the method of Pﬀaﬁ or 2-ΔΔCT.
2.10. Biochemical assessment
Serum insulin levels were assessed using an ELISA kit (DiaMetra,
Milano, Italy) with inter- and intra-assay coeﬃcient variances of
3.2–4.7%, respectively. The homeostasis model of assessment-insulin
resistance (HOMA-IR) was determined according to the suggested for-
mulas.
2.11. Randomization
Randomization assignment was conducted using computer-gener-
ated random numbers. Randomization and allocation concealment
were conducted by the researchers and participants and were carried
out by a trained staﬀ at the gynecology clinic. Another person, who was
not involved in the trial and not aware of random sequences, assigned
the subjects to the numbered bottles of capsules.
2.12. Statistical methods
To calculate the sample size, we used the standard formula sug-
gested for clinical trials by considering type one error (α) of 0.05 and
type two error (β) of 0.20 (power = 80%). Based on a previous study
(Nasri et al., 2017), we used 0.25 fold change as SD and 0.25 fold
change as the diﬀerence in mean (d) of gene expression of PPAR-γ as
primary variable. Based on this, we needed 16 subjects in each group.
Considering a dropouts of 4 subjects per group, we calculated to have
20 subjects per group.
The Shapiro-Wilk test was applied to control the normal distribution
of variables. Independent sample t-test was used to establish changes in
anthropometric measures and dietary intakes between the two groups.
To determine the eﬀects of omega-3 and vitamin E co-administration on
parameters of mental health, and gene expression related to insulin and
inﬂammation, we used independent sample t-test. Adjustment for
changes in baseline values of mental health parameters was performed
by analysis of covariance (ANCOVA) using general linear models.
P< 0.05 were considered statistically signiﬁcant. All statistical ana-
lyses conducted using the Statistical Package for Social Science version
18 (SPSS Inc., Chicago, Illinois, USA).
Table 1





GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
PPAR-γ F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
GLUT-1 F: TATCTGAGCATCGTGGCCAT 238 62.1
R: AAGACGTAGGGACCACACAG
IL-1 F: GCTTCTCTCTGGTCCTTGG 174 56
R: AGGGCAGGGTAGAGAAGAG
IL-8 F: GCAGAGGGTTGTGGAGAAGT 150 56
R: ACCCTACAACAGACCCACAC
TNF-α F: GTCAACCTCCTCTCTGCCAT 188 52
R: CCAAAGTAGACCTGCCCAGA
TGF-β F: TTGAGACTTTTCCGTTGCCG 227 56
R: CGAGGTCTGGGGAAAAGTCT
GAPDH, glyceraldehyde-3-Phosphate dehydrogenase; GLUT-1, glucose transporter 1; IL-
1, interleukin-1; IL-8, interleukin-8; PPAR-γ, peroxisome proliferator-activated receptor
gamma; TNF-α, tumor necrosis factor alpha; TGF-β, transforming growth factor beta.
Fig. 1. Summary of patient ﬂow diagram.
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3. Results
20 participants in both groups completed the trial out of 55 subjects
which were recruited in our study (15 subjects were excluded from the
study because of not meeting inclusion criteria), (Fig. 1). On average,
higher than 90% of capsules were taken in both groups.
There was no statistically signiﬁcant diﬀerence in mean age, height,
weight, BMI, WC, HC and METs levels at baseline and end-of-treatment
between the two groups (Table 2). After the 12-week intervention,
compared with the placebo, omega-3 and vitamin E co-supplementation
led to signiﬁcant improvements in mFG scores (− 0.7± 0.9 vs. −
0.2±0.5, P = 0.02), BDI score (− 2.2±2.0 vs. − 0.2± 1.3, P =
0.001), GHQ scores (− 5.5±4.6 vs. − 1.0± 2.3, P< 0.001) and
DASS scores (− 7.2± 5.2 vs. − 1.3±1.3, P<0.001). When we ad-
justed data for baseline values of mental health parameters (BDI, GHQ
and DASS scores), our ﬁndings did not alter. In addition, when we
adjusted data for baseline values of mental health parameters, age,
baseline BMI, WC, HC and mFG scores, our ﬁndings did not alter.
Compared to the placebo group, omega-3 and vitamin E co-sup-
plementation resulted in a signiﬁcant decrease in serum insulin levels
(− 1.8± 3.2 vs. +1.6± 5.9 µIU/mL, P = 0.02) and HOMA-IR (−
0.4±0.8 vs. +0.4±1.3, P = 0.03).
Considering the 3-day dietary records obtained during the inter-
vention, there was no statistically signiﬁcant diﬀerence in terms of
dietary macro- and micro-nutrient intakes between omega-3 and pla-
cebo groups (Data not shown).
We indicated that compared with the placebo, omega-3 and vitamin
E co-supplementation up-regulated PPAR-γ expression (P = 0.04), but
did not change GUT-1 expression in peripheral blood mononuclear cells
(PBMC) of subjects with PCOS (Fig. 2).
Table 2
General characteristics of study participants.
Placebo group (n = 20) Omega-3 fatty acids plus vitamin E group (n = 20) Pa
Age (y) 24.4± 4.7 22.3± 4.7 0.15
Height (cm) 161.9± 6.6 160.0± 6.1 0.33
Weight at study baseline (kg) 69.8± 17.1 73.6± 11.7 0.41
Weight at end-of-trial (kg) 69.4± 16.9 72.7± 11.8 0.47
Weight change (kg) − 0.4±1.1 − 0.9±1.5 0.27
BMI at study baseline (kg/m2) 26.5± 5.9 28.8± 5.1 0.18
BMI at end-of-trial (kg/m2) 26.3± 5.8 28.5± 5.1 0.21
BMI change (kg/m2) − 0.2±0.4 − 0.3±0.6 0.27
WC at study baseline (cm) 87.1± 12.4 90.0± 12.7 0.46
WC at end-of-trial (cm) 86.9± 12.2 89.6± 12.6 0.49
WC change (cm) − 0.2±0.6 − 0.4±0.5 0.24
HR at study baseline (cm) 98.7± 12.6 102.1± 12.1 0.40
HR at end-of-trial (cm) 98.6± 12.4 101.7± 13.1 0.44
HR change (cm) − 0.1±1.0 − 0.4±0.5 0.24
mF-G scores at study baseline 14.1± 3.6 15.8± 4.0 0.15
mF-G scores at end-of-trial 13.9± 3.3 15.1± 3.6 0.28
mF-G scores change − 0.2±0.5 − 0.7±0.9 0.02
MET-h/day at study baseline 27.1± 1.9 27.9± 2.1 0.26
MET-h/day at end-of-trial 27.2± 2.1 28.0± 2.2 0.25
MET-h/day change 0.1±0.6 0.1± 0.9 0.71
BDI total scores at baseline 15.8± 7.3 16.5± 8.3 0.77
BDI total scores at end-of-trial 15.6± 7.2 14.3± 7.9 0.59
BDI total scores change
Crude − 0.2±1.3 − 2.2±2.0 0.001
Adjustedb − 0.2±1.6 − 2.2±1.8 0.001
GHQ scores at baseline 46.1± 11.1 46.9± 11.3 0.80
GHQ scores at end-of-trial 45.1± 11.0 41.4± 11.8 0.31
GHQ scores change
Crude − 1.0±2.3 − 5.5±4.6 <0.001
Adjustedb − 1.0±3.5 − 5.5±3.8 <0.001
DASS scores at baseline 93.1± 21.1 94.9± 23.0 0.79
DASS scores at end-of-trial 91.7± 20.5 87.7± 22.1 0.55
DASS scores change
Crude − 1.3±1.3 − 7.2±5.2 <0.001
Adjustedb − 1.4±3.5 − 7.1±3.7 <0.001
Data are means± SDs.
BDI, beck depression inventory; DASS, depression anxiety and stress scale; GHQ, general health questionnaire; HC, hip circumference; mF-G, modiﬁed Ferriman Gallwey; METs, metabolic
equivalents; WC, waist circumference.
a Obtained from independent t-test.
b Adjusted based on baseline values.
Fig. 2. Eﬀect of 12-week supplementation with omega-3 fatty
acids plus vitamin E or placebo on expression ratio of PPAR-γ
and GLUT-1 gene in blood mononuclear cells of PCOS sub-
jects.
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We found that omega-3 and vitamin E co-supplementation, com-
pared with the placebo, down-regulated IL-8 (P = 0.003) and TNF-α
expression (P = 0.001), but did not aﬀect TGF-β expression in PBMC of
subjects with PCOS (Figs. 3 and 4).
4. Discussion
Although, beneﬁcial eﬀects of omega-3 and vitamin E co-supple-
mentation on metabolic proﬁles among subjects with PCOS had been
previously reported (Rahmani et al., 2017), to our knowledge, this
study is the ﬁrst report of the eﬀects of omega-3 fatty acids and vitamin
E co-administration on gene expression levels related to insulin and
inﬂammation in these subjects. It was shown that omega-3 and vitamin
E co-administration for 12 weeks among PCOS subjects had favorable
eﬀects on parameters of mental health and few gene expression related
to insulin and inﬂammation.
Patients with PCOS are susceptible to mental health disorders and
several metabolic complications, insulin resistance and inﬂammation
(Asemi et al., 2015; Foroozanfard et al., 2015). The current study de-
monstrated that omega-3 and vitamin E co-supplementation for 12
weeks in PCOS women improved parameters of mental health. Previous
studies have demonstrated that omega-3 fatty acids supplementation,
administered either adjunctively or as monotherapy, signiﬁcantly de-
creased depression symptom severity in pediatric and adolescent pa-
tients (Wozniak et al., 2007; McNamara et al., 2014). In addition, in a
study by Gautam et al. (2012), it was observed that antioxidant sup-
plement therapy as an adjuvant therapy was useful in subjects with
stress-induced psychiatric disorders. Another study has indicated that
pretreatment with EPA alone decreased the incidence of depression
during interferon-α treatment in hepatitis C population (Su et al.,
2014). Patients with depressive disorder exhibit elevated parameters of
peripheral (Dowlati et al., 2010) and central (Setiawan et al., 2015)
inﬂammation, and omega-3 and their bioactive metabolites have anti-
inﬂammatory and inﬂammation-resolving properties (Dalli et al.,
2015).
Our study documented that omega-3 and vitamin E co-supple-
mentation for 12 weeks in PCOS women, up-regulated PPAR-γ ex-
pression, without any change on GLUT-1 expression. In agreement with
our ﬁndings, 3.4 g/day of EPA and DHA intake for a period of 2–3
weeks up-regulated PPAR-γ gene expression levels (Anderson et al.,
2014). Likewise, PPAR-γ expression were signiﬁcantly increased by
ALA in human renal cell carcinoma cell line (Yang et al., 2013). Vitamin
E administration could up-regulate PPAR-γ expression in ApoE KO mice
(Tang et al., 2014). These results were in agreement with the other
ﬁndings that indicated vitamin E supplementation in rabbit sig-
niﬁcantly increased PPAR-γ expression in aorta (Bozaykut et al., 2014).
However, PPAR-γ gene expression was not aﬀected by 2400 mg/d of
ﬁsh oil supplementation among people with T2DM after 8 weeks
(Mansoori et al., 2015). PPAR-γ heterodimerizes with the retinoid X
receptor and modulate expressed levels of several genes encoding re-
lated to adipocyte diﬀerentiation, lipid and glucose metabolism
(Grindﬂek et al., 2000). Down-regulation PPAR-γ plays a key function
in the pathology of diabetes, CVD and cancer (Strakova et al., 2005).
Previous studies have shown that fatty acids are the natural ligands of
PPAR-γ, and therefore ALA is able to activate PPAR-γ production (Gani,
2008; Itoh et al., 2008). In addition, vitamin E may increase gene ex-
pression of PPAR-γ through downregulating monocyte recruitment and
scavenger receptor CD36 expression (Munteanu et al., 2006). Omega-3
and vitamin E co-supplementation may work better than single sup-
plementation. In addition, omega-3 plus vitamin E supplementation
might have a strong synergistic eﬀect on insulin metabolism and in-
ﬂammatory markers.
The results of this study showed that omega-3 and vitamin E co-
supplementation for 12 weeks in PCOS subjects down-regulated IL-1,
IL-8 and TNF-α expression in comparison with the placebo, but did not
aﬀect IL-6 and TGF-β expression. In agreement with our study, sup-
pressing TNF-α expression by EPA was reported in human monocytic
THP-1 cells (Zhao et al., 2004). Other researchers have also demon-
strated that omega-3 supplementation signiﬁcantly decreased gene ex-
pression of TNF-α and IL-1 (Endres et al., 1989; Novak et al., 2003). In
Fig. 3. Eﬀect of 12-week supplementation with omega-3 fatty acids plus vitamin E or placebo on expression ratio of IL-1, IL-6 and IL-8 gene in blood mononuclear cells of PCOS subjects.
Fig. 4. Eﬀect of 12-week supplementation with omega-3 fatty
acids plus vitamin E or placebo on expression ratio of TNF-α
and TGF-β gene in blood mononuclear cells of PCOS subjects.
GLUT-1, glucose transporter 1; IL-1, interleukin-1; IL-8, in-
terleukin-8; PCOS, polycystic ovary syndrome; PPAR-γ, per-
oxisome proliferator-activated receptor gamma; TNF-α,
tumor necrosis factor alpha; TGF-β, transforming growth
factor beta.
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addition, vitamin E supplementation in rats with alcoholic chronic
pancreatitis signiﬁcantly decreased gene expression of TNF-α (Monteiro
et al., 2012). Increased inﬂammatory cytokines in PCOS subjects would
result in increased risk for the development of atherosclerosis and in-
fertility (Pawelczak et al., 2014). Omega-3 intake may have a potent
anti-inﬂammatory eﬀect due to the modulation of omega-3 fatty acids-
derived lipid mediators (Serhan and Savill, 2005). A recent study in-
dicated a G protein-coupled receptor-speciﬁc pathway involved in NF-
kB down-regulation by the omega-3 (Arita et al., 2005), which in turn
could down-regulate NF-kB -induced TNF-α formation. Vitamin E can
decrease gene expression related to inﬂammatory signaling pathways
through speciﬁc enzymes involved in signal transduction modulation
such as protein kinase C, phosphatidylinositol 3-kinase, lipoxygenases,
phospholipase A2 and diacylglycerol kinase (Azzi et al., 2004).
There were some limitations in this study. Firstly, omega-3 and vi-
tamin E levels at baseline and at the end-of-trial were not evaluated due
to funding limitations. Besides, the evaluation of gene expression of
other insulin-dependent transporters such as GLUT-4 or other post-re-
ceptor steps including insulin receptor substrate 1 or-2 were not con-
ducted in this work. Measurement of these pathways is suggested to be
done in the future studies. It is also diﬃcult to conclude when two
products are being used against placebo. Therefore, further studies are
necessary with single supplementation for each comparison with co-
supplementation to quantify the beneﬁcial eﬀects of each on gene ex-
pression related to insulin and inﬂammatory cytokines. Although the
evaluation of omega-3 and vitamin E co-supplementation among those
who receive combined contraceptives and metformin and those who do
not receive is interesting, its performance is suggested in next studies.
Moreover, we had not measured serum levels of lipid proﬁles and gene
expression related to lipid metabolism in the current study.
Overall, omega-3 and vitamin E co-supplementation for 12 weeks in
PCOS subjects signiﬁcantly improved parameters of mental health, and
gene expression of PPAR-γ, IL-8 and TNF-α, but did not inﬂuence ex-
pressed levels of GLUT-1, IL-6 and TGF-β. This suggests omega-3 and
vitamin E co-supplementation may confer advantageous therapeutic
potential for patients with PCOS management. Further research is
needed in other patients with longer periods and higher dosage of
omega-3 to determine the safety of this supplemental approach.
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